by 93% of the respondents as 'most important' to their patients, followed by pain on swallowing (87%) and difficulty speaking (73%). Nurses ranked OM very high (92%) relative to other supportive care issues faced by cancer patients. Nurses were overwhelmingly identified (81%) as the healthcare professionals responsible for the initial evaluation and management of OM in their practice setting. Fifty-seven percent of respondents reported that they did not have specific institutional guidelines in place for the management of OM. The survey revealed myriad products used as first-and second-line agents in the management of OM pain (see Table 1 ). The multi-agent rinse 'magic mouthwash' (pharmacy compounded), oral pain medications, and sucralfate were the primary management strategies used in an attempt to alleviate the pain caused by OM. The effectiveness of these first-line agents in relieving the pain of OM was dismal, with 67% of the respondents rating them as only minimally effective. These survey results are not surprising. They reinforce the fact that OM remains a significant clinical problem that is currently being treated with ineffective agents. Many nurses still do not have specific clinical guidelines to assist them in the management of OM.
Pathophysiology
Historically, OM was thought to arise solely as a consequence of epithelial injury. Both chemotherapy and radiation therapy were believed to target non-specifically the rapidly proliferating cells of the basal epithelium, causing a direct inhibitory effect on DNA replication and mucosal cell proliferation. This inhibition, it was hypothesized, led to a reduced renewal capability of the basal epithelium resulting in atrophy, collagen breakdown, and eventual ulceration. Furthermore, it was believed that the process was facilitated by trauma and the entry of oral micro-organisms. However, recent clinical investigations have shown that submucosal damage actually precedes the appearance of epithelial lesions by as much as one week. 4 Originally, OM was thought to be a four-phase process consisting of an initial inflammatory phase, an epithelial phase, an ulceration phase, and, finally, a 
healing phase. Sonis et al. 5 proposed a five-phase model for the pathobiology of OM. Phase I, 'initiation,' occurs when radiation therapy and/or chemotherapy cause damage to the DNA in the basal epithelium, leading to the release of reactive oxygen species (ROS), which are normally a natural by-product of oxygen metabolism and have an important role in cell signaling.
However, during times of stress ROS levels can increase dramatically, which can result in cell damage. In the case of OM, the ROS surge leads to further trauma to the cells and blood vessels in the submucosa. At this stage, the mucosa still appears normal on examination, although all the events that ultimately lead to ulceration have already been triggered. Denham 
Literature Review
Unfortunately, OM is an inevitable, costly, and debilitating consequence of Criteria (NCI-CTC), 9 the Oral Mucositis Assessment Scale, 10 and the Oral Assessment Guide. 11 Each of these systems is useful in select situations, but no one scale has gained widespread acceptance for clinical application (see Table 2 ). Keratinocyte growth factor (KGF) has become popular in the Anatomical and functional assessment
Coating agents are also commonly cited, with most research evaluating sucralfate and 'magic mouthwash.' Kostler and colleagues reviewed eight studies published between 1988 and 2000 that investigated the efficacy of sucralfate rinses in radiation patients. 16 They concluded that sucralfate seems to have little, if any, benefit compared with standard oral hygiene and symptomatic treatment of OM. A clinical study comparing pain relief and overall pain scores associated with salt and bicarbonate alone, chlorhexidine, and magic mouthwash with lidocaine, diphenhydramine, and Maalox ® was conducted by Dodd et al. 17 There was no difference in the severity or duration of OM among any of the three arms. Gelclair ® , a newer barrier agent, has
shown promise in decreasing pain resulting from mucositis, apthous ulcers, and oral surgery. for radiation-induced oral mucositis (see Table 3 ).
Risk Factors
OM is influenced by a variety of patient-and treatment-related risk factors. This combination significantly increases the risk and severity of OM.
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Patient Assessment
OM requires the ongoing assessment and monitoring of the oral cavity. It should be systematically assessed pre-treatment to establish a baseline for all future comparisons, routinely during treatment, and post-treatment. The goal of these examinations is to improve or maintain a patient's functional status. 21 However, while the need for regular oral assessment is recognized, there is no consensus among the many existing clinical guidelines and oral care standards as to which rating/grading scales should be used. Ideally, a scale for OM should be objective, reliable, and valid for all clinical and research situations. 22 To date, there are no universal standards of oral care
and no assessment tools that fit all clinical settings.
Preventive Strategies
OM can seldom be prevented. Therefore, the aim of treatment is to reduce its severity. Palifermin and amifostine are two products currently being used to reduce the extent and severity of OM. Palifermin is a recombinant KGF that stimulates the replication and maturation of epithelial cells. Palifermin has multiple mechanisms of action, including downregulation of pro-inflammatory cytokines, inhibition of epithelial cell DNA damage and apoptosis, and stimulation of epithelial cell growth, differentiation, and migration. 23 Palifermin has been approved in the US for use in patients with hematological malignancies who are undergoing total body irradiation and high-dose chemotherapy in preparation for peripheral blood stem cell transplant, in order to decrease the incidence and duration of severe OM. Phase III trials conducted by Spielberger et al. 13 found that palifermin administered three days before transplant and three days after transplant showed a reduction in the incidence of grade 3 and 4 OM (63% with palifermin versus 98% with placebo).
Spielberger found the duration of grade 3 and 4 OM was reduced from nine to six days with the use of palifermin. Amifostine is a radioprotectant that is currently approved for the prevention of radiation-induced xerostomia. In addition, the United States Pharmacopoeia recognizes an accepted off-label use of amifostine to reduce the incidence of mucositis in patients receiving chemotherapy or radiation alone, or in chemoradiotherapy. 24 This agent is believed to act as a free radical scavenger to protect healthy cells against the effects of radiotherapy or chemotherapy. The impact of amifostine on OM is probably due to an indirect effect related to the enhancement of saliva secretion, which has been demonstrated to reduce the intensity of mucositis.
25
Treatment Strategies
There are a number of targeted therapies in current use that aim to reduce the severity of OM and manage the associated pain. The most common interventions were identified in the ONS Mucositis Survey (see Table 1 ). More 
unpredictable, as the main drawback of these multimixture formulas is alterations in taste and the potential for further trauma to the oral tissue as a result of the numbness produced by the local anesthetic. There have been very few controlled clinical trials to determine the effectiveness of 'magic mouthwash' and compounded mouthwashes are not recommended in the MASCC guidelines (see Table 3 ). Sucralfate is a therapeutic agent that has been used in patients with peptic ulcer disease. Sucralfate is a basic aluminum salt of sucrose sulfate and is sometimes used as an oral suspension to treat OM. It produces a paste-like protective coating over the ulcerated mucosa.
Sucralfate was believed to increase the local production of prostaglandin E2, leading to increased blood flow and production of mucus. 26 Prostaglandin E2
has been reported to have cytoprotective effects on a variety of tissues and can be a mucosal protectant in patients receiving high-dose chemotherapy.
However, the effectiveness of sucralfate in treating OM is questionable and its use is not recommended by MASCC. It is recommended that Gelclair be used three to four times per day. It has also been shown to be effective in alleviating pain following the ablation of soft tissue oral lesions after surgical laser treatment. 27 Gelclair may not eliminate the Opiates have been the cornerstone of pain management for moderate to 
severe OM. They are often started at the onset of pain and titrated throughout the treatment phase or until the OM has resolved. Opiates are the best-studied approach for the management of severe OM pain. The WHO recommends morphine as the opioid of choice for the management of severe pain. 30 Elting and colleagues 31 
